

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/063712 A3

(51) International Patent Classification?: C12Q 1/68, C12P
19/34, C07H 21/02, 21/04, G01N 33/574, C07K 14/435

(21) International Application Number:

PCT/US2004/000447

(22) International Filing Date: 9 January 2004 (09.01.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/438,861

9 January 2003 (09.01.2003) US

(71) Applicant (for all designated States except US): CHILDREN'S MEDICAL CENTER CORPORATION
[US/US]; 55 Shattuck Street, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ZETTER, Bruce
[US/US]; 41 Grove Street, Wayland, MA 01778 (US).
HUTCHINSON, Lloyd [US/US]; 69 Fuller Street, Brook-
line, MA 02446 (US). BAO, Lere [CN/US]; 145 Day
Street, Newton, MA 02466 (US).

(74) Agents: RESNICK, David, S. et al.; Nixon Peabody LLP,
100 Summer Street, Boston, MA 02110-2131 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
31 March 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER

(57) Abstract: We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasia (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316) has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316) in a biological test sample obtained from the patient are provided.

BEST AVAILABLE COPY

WO 2004/063712 A3